Content about Bayer

WAYNE, N.J. — Bayer HealthCare and Onyx Pharmaceuticals are seeking approval for a new drug to treat tumors of the gut, the companies said.

Bayer and Onyx announced the submission to the Food and Drug Administration of an application seeking approval for regorafenib in patients with gastrointestinal stromal tumors, or GIST. Bayer developed the drug and formed a partnership with Onyx in 2011, whereby Onyx will receive a royalty on future global net sales of the drug in cancer-related indications. Both companies will promote the drug in the United States.

Bayer has been stepping up its game behind its Bayer Advanced Aspirin brand in an attempt to recreate its brand identity from a healthy heart supplement for people who’ve had a heart attack to what Bayer Aspirin had been in its heyday: the internal analgesic of choice.

PARSIPPANY, N.J. — Significant product recalls and the ongoing recession have driven consumer behavior change in the OTC aisle, according to a new report published Tuesday by Kline. In addition, road blocks to savings, such as reimbursement of OTC medicines under flexible spending accounts, were recently put in place with the new requirement that those medicines now to be prescribed by a physician in order to qualify for reimbursement. Approximately 1-in-5 respondents have used FSAs to purchase OTC drugs or nutritional supplements in the past, the report noted.

WAYNE, N.J., and SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has granted priority review for an investigational cancer treatment created by Bayer and Onyx Pharmaceuticals.

The companies said Bayer's new drug application for oral multikinase inhibitor regorafenib initially was filed in April for the treatment of patients with metastatic colorectal cancer, whose disease has progressed after approved standard therapies. The FDA grants priority review to medicines that provide a treatment where little or no adequate therapy exists.

According to DSN OTC expert Michael Johnsen, there is a great opportunity for all vendors to sell more by engaging with retailer education programs. Below are MJ's picks for hot products in health and wellness.

WAYNE, N.J. — An experimental drug made by Bayer HealthCare extended the length of time that patients with gastrointestinal tumors survived without their disease getting worse, according to results of a late-stage clinical trial released Monday.

SOUTH SAN FRANCISCO, Calif. — Two drug makers are looking to win approval for an experimental drug in patients with colorectal cancer that has spread to other parts of the body.

Onyx Pharmaceuticals announced that Bayer HealthCare had submitted a regulatory approval application to the Food and Drug Administration for regorafenib in patients with metastatic colorectal cancer.

PITTSBURGH — Bayer on Friday announced that it is providing monetary support for disaster relief efforts through a $25,000 donation from the Bayer USA Foundation to the American Red Cross of southwestern Indiana. The state of Indiana was among several states affected by tornadoes on March 2, which caused extensive damage to rural communities such as Henryville, Clarksville and Newburgh.

MORRISTOWN, N.J. — To encourage consumers to rethink aspirin for pain relief — according to a recent Bayer survey, only 8% of respondents reported taking aspirin more often that other OTC pain relievers — Bayer on Tuesday issued the Fast Relief Challenge and is giving away 100,000 bottles of Bayer Advanced Aspirin so consumers can put the pain reliever to the test.

WAYNE, N.J. — The Food and Drug Administration has approved a new formulation of a drug for postmenopausal women.

Bayer HealthCare Pharmaceuticals said the FDA approved a lower-dose formulation of Angeliq (drospirenone and estradiol) tablets, used to treat moderate to severe vasomotor symptoms due to menopause in women who have a uterus. The new formulation contains 0.25-mg drospirenone and 0.5-mg estradiol, while the previously approved formulation contained 0.5-mg drospirenone and 1-mg estradiol.

MORRISTOWN, N.J. — Bayer recently engaged the Goldstein Group to rejuvenate the cough-cold Neo-Synephrine brand and improve the brand's identity on shelf.

The brand design group employs such tools as its trademarked Shelf Sight Sequence, a packaging design service that improves shelf presence with "a visual vocabulary of proprietary colors, shapes, symbols and verbiage ... to trigger the consumer's purchasing impulse at first sight."

TARRYTOWN, N.Y. — Bayer HealthCare and Regeneron Pharmaceuticals have started a late-stage clinical trial in China to evaluate a drug for eye disorders, the companies said Monday.

The drug makers announced the start of the phase-3 "SIGHT" trial of Eylea (aflibercept) injection for the treatment of the neovascular form of age-related macular degeneration, also known as wet AMD. The companies said the trial, which will include about 300 patients, will be the largest retinal trial conducted in China.